Mark Hensley Joins RBL LLC as Senior Adviser
In a significant development for the biotech community, RBL LLC, a leading venture creation studio focused on innovative biomedical technologies, has announced the appointment of Mark Hensley as a senior adviser. This strategic move is expected to enhance RBL's mission of rapidly constructing companies centered around lifesaving medical technologies.
Hensley, a seasoned professional with over 15 years of experience in the biotechnology sector, brings a wealth of expertise in areas such as corporate strategy, venture financing, and business development. His extensive background equips him to propel the commercialization of breakthrough life sciences technologies at RBL’s Houston-based facility.
Paul Wotton, CEO and managing partner of RBL LLC, expressed confidence in Hensley's capabilities, noting that his impressive history of handling large business transactions will play an essential role in the company's growth. "Following our launch in October, we are on track to significantly advance our objectives with Mark's guidance," Wotton stated.
Hensley’s career is marked by a successful track record in identifying high-potential biotech opportunities and leading various ventures in therapeutic fields, including transplant, immunology, and rare diseases. His experience is anticipated to be a valuable asset for RBL as it seeks to launch multiple innovative clinical-stage biotech companies.
"This is an excellent opportunity to join RBL LLC at a pivotal time," Hensley remarked. He expressed his eagerness to work with the talented team at RBL and to cultivate strategic partnerships that will drive forward the development of impactful therapies for patients globally.
Before joining RBL LLC, Hensley was the Chief Operating Officer at Heron Therapeutics, where he focused on bringing into fruition therapeutic innovations that enhance patient care. Previously, he excelled as the CEO of Veloxis Pharmaceuticals, successfully executing a major acquisition that broadened the company’s reach in nephrology, and had an integral role in a billion-dollar sell-side transaction as the Chief Commercial Officer.
Hensley holds a Bachelor of Science degree in biology with a minor in chemistry from the University of North Texas, and he has proven expertise across various facets of the biotechnology and life sciences landscape. His goal at RBL LLC will be to foster an environment conducive to launching new biotech initiatives.
About RBL LLC: RBL LLC is a pioneering biotech venture creation studio based in Houston, focused on accelerating the development of breakthrough medical technologies via company formation. The venture studio provides essential resources, including infrastructure, financial assistance, and strategic guidance, to entrepreneurs and innovators. For more information, visit
RBL LLC's website.
Contact
For media inquiries regarding this announcement, reach out to Russo Partners: